Vertex Pharmaceuticals (NASDAQ: VRTX) last traded at $548.05, up 1.44% on the session. The quote above updates while this page is open; the figures below are drawn from Vertex Pharmaceuticals’s own filings and are restated only when a new one is published.
Vertex Pharmaceuticals trades on NASDAQ under the ticker VRTX. It is classified in the Healthcare sector, Biotech industry. Its market capitalisation is $138.91 billion.
Healthcare sectorBiotechListed on NASDAQ
Valuation measures for Vertex Pharmaceuticals, derived from the latest quote and its most recent SEC filing.
| Market cap | $138.91B |
|---|---|
| Enterprise value | $139.94B |
| P/E ratio | 31.92 |
| Price / sales | 11.04 |
| Price / book | 6.86 |
| Beta | 0.49 |
Trailing-twelve-month figures tagged in Vertex Pharmaceuticals's XBRL filings with the SEC.
| Revenue (TTM) | $12.59B |
|---|---|
| Net income (TTM) | $4.41B |
| EPS (TTM) | $17.17 |
| Operating margin | 37.95% |
| Return on equity | 21.76% |
| Cash | $6.14B |
Range and volume for VRTX over the past 52 weeks.
| 52-week high | $555.32 |
|---|---|
| 52-week low | $374.17 |
| Volume | 940.1K |
| Average volume | 1.55M |
| Previous close | $540.26 |
Other Healthcare companies tracked on FurlPay Markets.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.